Table 2 VSR dedicated management
|  | 30-day-survival group (n = 18) | 30-day-mortality group (n = 14) | p-value |
|---|---|---|---|
Received IABP | 14 (78%) | 11 (79%) | > 0.99 |
Upfront IABP | 6 (43%) | 1 (9%) | 0.09 |
IABP duration (days) | 15 (9–24) | 10 (4–14) | 0.06 |
VSR Intervention | Â | Â | 0.18 |
 Surgical repair | 11 (61%) | 4 (29%) |  |
 Percutaneous device closure | 4 (22%) | 5 (36%) |  |
 No intervention | 3 (17%) | 5 (36%) |  |
Residual VSD | 3 (21%) | 1 (13%) | > 0.99 |
VSR diagnosis -to– Intervention (days) | 31 (16–69) | 14 (6–18) | 0.034 |